| scholarly article | Q13442814 |
| P50 | author | Barbara Savoldo | Q109983471 |
| P2093 | author name string | Chung-Che Chang | |
| Youli Zu | |||
| Jianguo Wen | |||
| Wenjing Tao | |||
| Lauren C King | |||
| Hangwen Li | |||
| Jessica A Foglesong | |||
| P2860 | cites work | A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma | Q24319940 |
| Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance | Q24644883 | ||
| Cancer/testis antigens: an expanding family of targets for cancer immunotherapy | Q28215652 | ||
| Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms | Q28292633 | ||
| Critical appraisal of the side population assay in stem cell and cancer stem cell research | Q28304721 | ||
| Cancer statistics, 2007 | Q29547293 | ||
| Non-side-population hematopoietic stem cells in mouse bone marrow. | Q33248095 | ||
| A phase 2 study of bortezomib in relapsed, refractory myeloma | Q33348702 | ||
| High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells | Q33806895 | ||
| Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications | Q33820610 | ||
| Detection of monoclonal immunoglobulin heavy chain gene rearrangement (FR3) in Thai malignant lymphoma by High Resolution Melting curve analysis | Q33914661 | ||
| Cancer stem cells: controversies in multiple myeloma | Q34462722 | ||
| PCR assays detect B-lymphocyte clonality in formalin-fixed, paraffin-embedded specimens of classical hodgkin lymphoma without microdissection | Q34615121 | ||
| The cancer/testis genes: review, standardization, and commentary. | Q35635779 | ||
| Progress in myeloma stem cells | Q35824980 | ||
| Cancer/Testis Antigen MAGE-C1/CT7: new target for multiple myeloma therapy. | Q35846167 | ||
| Multiple myeloma cancer stem cells | Q37029171 | ||
| Cancer stem cells in multiple myeloma. | Q37133709 | ||
| Development of target-specific treatments in multiple myeloma | Q37771370 | ||
| Can we change the disease biology of multiple myeloma? | Q38062038 | ||
| Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma. | Q38151195 | ||
| Small molecule antibody targeting HLA class I inhibits myeloma cancer stem cells by repressing pluripotency-associated transcription factors | Q39376795 | ||
| CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype | Q39399792 | ||
| Luteinizing Hormone-Releasing Hormone (LHRH)-I antagonist cetrorelix inhibits myeloma cell growth in vitro and in vivo | Q39633995 | ||
| Enhanced expression of cancer testis antigen genes in glioma stem cells | Q39750817 | ||
| P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells | Q40028561 | ||
| Clinical activity of arsenic trioxide for the treatment of multiple myeloma | Q43841477 | ||
| Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition. | Q45927659 | ||
| Infrequent and low expression of cancer-testis antigens located on the X chromosome in colorectal cancer: implications for immunotherapy in South African populations | Q46763984 | ||
| MAGE-A10 cancer/testis antigen is highly expressed in high-grade non-muscle-invasive bladder carcinomas. | Q54284949 | ||
| The proliferative potential of myeloma plasma cells manifest in the SCID-hu host | Q73160451 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 711-719 | |
| P577 | publication date | 2014-05-29 | |
| P1433 | published in | British Journal of Haematology | Q4970200 |
| P1476 | title | High throughput quantitative reverse transcription PCR assays revealing over-expression of cancer testis antigen genes in multiple myeloma stem cell-like side population cells | |
| P478 | volume | 166 |
| Q26785497 | Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction? |
| Q43068239 | Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions |
| Q90733980 | Involvement of X-chromosome Reactivation in Augmenting Cancer Testis Antigens Expression: A Hypothesis |
| Q24318387 | Luzp4 defines a new mRNA export pathway in cancer cells |
| Q102061308 | Mesenchymal stem/stromal cells: Developmental origin, tumorigenesis and translational cancer therapeutics |
Search more.